Ennio Giulio Favalli1, Serena Bugatti2,3, Catherine Klersy4, Martina Biggioggero5, Silvia Rossi2, Orazio De Lucia5, Francesca Bobbio-Pallavicini2, Antonella Murgo5, Silvia Balduzzi2, Roberto Caporali5,6, Carlomaurizio Montecucco2,3. 1. Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Via Gaetano Pini, 9, 20122, Milan, Italy. enniofavalli@me.com. 2. Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. 3. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. 4. Unit of Clinical Epidemiology & Biometry, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. 5. Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Via Gaetano Pini, 9, 20122, Milan, Italy. 6. Department of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy.
Abstract
BACKGROUND: Prevalence and outcomes of coronavirus disease (COVID)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis. METHODS: The study was conducted in the arthritis outpatient clinic at two large academic hospitals in the COVID-19 most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence of severe acute respiratory syndrome-coronavirus-2 nasopharyngeal swab positivity and the occurrence of acute respiratory illness (fever and/or cough and/or dyspnea), administered face-to-face or by phone to consecutive patients from 25 February to 20 April 2020. COVID-19 cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID-19 development was evaluated. RESULTS: The study population included 2050 adults with chronic inflammatory arthritis receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs). Laboratory-confirmed COVID-19 and highly suspicious infection were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID-19 (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs, age, sex, and comorbidities were observed. CONCLUSIONS: During the COVID-19 outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection. TRIAL REGISTRATION: Retrospectively registered. Not applicable.
BACKGROUND: Prevalence and outcomes of coronavirus disease (COVID)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis. METHODS: The study was conducted in the arthritisoutpatient clinic at two large academic hospitals in the COVID-19 most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence of severe acute respiratory syndrome-coronavirus-2 nasopharyngeal swab positivity and the occurrence of acute respiratory illness (fever and/or cough and/or dyspnea), administered face-to-face or by phone to consecutive patients from 25 February to 20 April 2020. COVID-19 cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID-19 development was evaluated. RESULTS: The study population included 2050 adults with chronic inflammatory arthritis receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs). Laboratory-confirmed COVID-19 and highly suspicious infection were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID-19 (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs, age, sex, and comorbidities were observed. CONCLUSIONS: During the COVID-19 outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection. TRIAL REGISTRATION: Retrospectively registered. Not applicable.
Authors: Jason Phua; Li Weng; Lowell Ling; Moritoki Egi; Chae-Man Lim; Jigeeshu Vasishtha Divatia; Babu Raja Shrestha; Yaseen M Arabi; Jensen Ng; Charles D Gomersall; Masaji Nishimura; Younsuck Koh; Bin Du Journal: Lancet Respir Med Date: 2020-04-06 Impact factor: 30.700
Authors: Christopher M Petrilli; Simon A Jones; Jie Yang; Harish Rajagopalan; Luke O'Donnell; Yelena Chernyak; Katie A Tobin; Robert J Cerfolio; Fritz Francois; Leora I Horwitz Journal: BMJ Date: 2020-05-22
Authors: Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell Journal: Lancet Date: 2020-05-19 Impact factor: 79.321
Authors: Paul Moss; Francis Berenbaum; Giuseppe Curigliano; Ayelet Grupper; Thomas Berg; Shanti Pather Journal: Vaccine Date: 2022-05-27 Impact factor: 4.169
Authors: Martin Bergman; Christopher D Saffore; Katherine J Kim; Pankaj A Patel; Vishvas Garg; Si Xuan; Haley B Naik Journal: Adv Ther Date: 2021-09-13 Impact factor: 3.845
Authors: Maryam A Adas; Edward Alveyn; Emma Cook; Mrinalini Dey; James B Galloway; Katie Bechman Journal: Expert Rev Clin Immunol Date: 2021-12-29 Impact factor: 4.473